{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-24-000051","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.170525+00:00","generated_at":"2026-06-02T06:03:50.172159+00:00","sec_items":["2.02","4.01","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Recursion posts Q1 net loss $91.4M; replaces EY with PwC after material weakness","bullets":["Net loss of $91.4M, up from $65.3M YoY; revenue $13.8M, up from $12.1M.","Cash $296.3M; operating cash burn $102.3M; annual bonuses and accrual payments drove increase.","Auditor change: EY dismissed, PwC appointed; material weakness in revenue estimation control identified for FY2023.","Phase 2 readouts expected: CCM (REC-994) Q3 2024, NF2 (REC-2282) Q4 2024, FAP (REC-4881) H1 2025.","Multi-year Helix agreement to access de-identified genomic and health records for AI model training."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-24-000051","json":"https://secwatch.observer/filing/0001601830-24-000051.json","markdown":"https://secwatch.observer/filing/0001601830-24-000051.md","text":"https://secwatch.observer/filing/0001601830-24-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000051/0001601830-24-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000051/rxrx-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:03:50.172159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab28b6d1da4c863cc2c6bb89b877a96cebbeb46d","claim":"RECURSION PHARMACEUTICALS, INC. dismissed Ernst & Young LLP as its auditor.","evidence_excerpt":"On May 7, 2024, the Audit Committee also dismissed Ernst & Young LLP (\"EY\") as our independent registered public accounting firm, beginning in the second fiscal quarter.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000051/0001601830-24-000051-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Ernst & Young LLP"},{"label":"Successor","value":"PricewaterhouseCoopers LLP"}]},{"claim_id":"c68bfeb9ced798fbd81bbd0433b18874af5a10ea","claim":"RECURSION PHARMACEUTICALS, INC. engaged PricewaterhouseCoopers LLP as its auditor.","evidence_excerpt":"on May 7, 2024, the Audit Committee approved the appointment of PricewaterhouseCoopers LLP (\"PwC\") as our independent registered public accounting firm, effective upon completion of PwC’s standard client acceptance process.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000051/0001601830-24-000051-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"PricewaterhouseCoopers LLP"}]},{"claim_id":"4cf0fa275e6a2d64ada09b4b43a235f65eaa78b6","claim":"RECURSION PHARMACEUTICALS, INC. reported financial results for first quarter ending March 31, 2024.","evidence_excerpt":"On May 9, 2024, the Company issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000051/0001601830-24-000051-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ending March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}